ALKBH5 could promote the expression of PD‐L1 in intrahepatic cholangiocarcinoma16 and the deletion of ALKBH5 would sensitise melanoma and CRC to immunotherapy,40 which indicated that ALKBH5 might be a potential biomarker for immune checkpoint blockade therapy in multiple cancers. This evidence concerns the gene CD274 and colorectal carcinoma.